Literature DB >> 22904561

Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Krishna C Chimalakonda1, Kathryn A Seely, Stacie M Bratton, Lisa K Brents, Cindy L Moran, Gregory W Endres, Laura P James, Paul F Hollenberg, Paul L Prather, Anna Radominska-Pandya, Jeffery H Moran.   

Abstract

Abuse of synthetic cannabinoids (SCs), such as [1-naphthalenyl-(1-pentyl-1H-indol-3-yl]-methanone (JWH-018) and [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone (AM2201), is increasing at an alarming rate. Although very little is known about the metabolism and toxicology of these popular designer drugs, mass spectrometric analysis of human urine specimens after JWH-018 and AM2201 exposure identified monohydroxylated and carboxylated derivatives as major metabolites. The present study extends these initial findings by testing the hypothesis that JWH-018 and its fluorinated counterpart AM2201 are subject to cytochrome P450 (P450)-mediated oxidation, forming potent hydroxylated metabolites that retain significant affinity and activity at the cannabinoid 1 (CB(1)) receptor. Kinetic analysis using human liver microsomes and recombinant human protein identified CYP2C9 and CYP1A2 as major P450s involved in the oxidation of the JWH-018 and AM2201. In vitro metabolite formation mirrored human urinary metabolic profiles, and each of the primary enzymes exhibited high affinity (K(m) = 0.81-7.3 μM) and low to high reaction velocities (V(max) = 0.0053-2.7 nmol of product · min(-1) · nmol protein(-1)). The contribution of CYP2C19, 2D6, 2E1, and 3A4 in the hepatic metabolic clearance of these synthetic cannabinoids was minimal (f(m) = <0.2). In vitro studies demonstrated that the primary metabolites produced in humans display high affinity and intrinsic activity at the CB(1) receptor, which was attenuated by the CB(1) receptor antagonist (6aR,10aR)-3-(1-methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (O-2050). Results from the present study provide critical, missing data related to potential toxicological properties of "K2" parent compounds and their human metabolites, including mechanism(s) of action at cannabinoid receptors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904561      PMCID: PMC3477201          DOI: 10.1124/dmd.112.047530

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  53 in total

1.  Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies.

Authors:  P L Prather; N A Martin; C S Breivogel; S R Childers
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

2.  In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist.

Authors:  Qiang Zhang; Peng Ma; Marcus Iszard; Richard B Cole; Weiqun Wang; Guangdi Wang
Journal:  Drug Metab Dispos       Date:  2002-10       Impact factor: 3.922

Review 3.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

4.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors.

Authors:  N J Proctor; G T Tucker; A Rostami-Hodjegan
Journal:  Xenobiotica       Date:  2004-02       Impact factor: 1.908

5.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

Review 6.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

Review 7.  Cardiovascular system effects of marijuana.

Authors:  Reese T Jones
Journal:  J Clin Pharmacol       Date:  2002-11       Impact factor: 3.126

8.  Spicy seizure.

Authors:  Sadip Pant; Abhishek Deshmukh; Bhagirath Dholaria; Varinder Kaur; Samayuktha Ramavaram; Mary Ukor; Gerson A Teran
Journal:  Am J Med Sci       Date:  2012-07       Impact factor: 2.378

9.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

10.  Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation.

Authors:  Amy C Young; Evan Schwarz; Genevieve Medina; Adebisi Obafemi; Sing-Yi Feng; Colin Kane; Kurt Kleinschmidt
Journal:  Am J Emerg Med       Date:  2011-07-29       Impact factor: 2.469

View more
  52 in total

1.  Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'.

Authors:  Verena Angerer; Florian Franz; Bernd Schwarze; Bjoern Moosmann; Volker Auwärter
Journal:  J Anal Toxicol       Date:  2016-01-27       Impact factor: 3.367

2.  K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.

Authors:  Rita G McKeever; David Vearrier; Dorian Jacobs; Gregory LaSala; Jolene Okaneku; Michael I Greenberg
Journal:  J Med Toxicol       Date:  2015-03

3.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Authors:  Ariane Wohlfarth; Marisol S Castaneto; Mingshe Zhu; Shaokun Pang; Karl B Scheidweiler; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

Review 4.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

Review 5.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

6.  First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

Authors:  Ariane Wohlfarth; Shaokun Pang; Mingshe Zhu; Adarsh S Gandhi; Karl B Scheidweiler; Hua-fen Liu; Marilyn A Huestis
Journal:  Clin Chem       Date:  2013-09-06       Impact factor: 8.327

7.  CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48.

Authors:  Niels Bjerre Holm; Line Marie Nielsen; Kristian Linnet
Journal:  AAPS J       Date:  2015-05-23       Impact factor: 4.009

8.  Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.

Authors:  Krishna C Chimalakonda; Laura P James; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Lett       Date:  2013-03

9.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

10.  Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Xiaohong Chen; Hua-fen Liu; Marilyn A Huestis
Journal:  Anal Chem       Date:  2013-03-18       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.